Smart nebulizer technology

Drug delivery that only happens when it can reach the lungs.

Conventional nebulizers fire continuously , half the drug is lost to exhale. PulmoSense detects each breath and delivers aerosol only during inhalation, closed-loop controlled and validated in-silico.

See it live View results
98–99%
PulmoSense delivery efficiency
~33%
Conventional efficiency
4
Patient profiles validated
30ms
Piezo mesh response time
Breathing monitor Live
12
bpm
INHALE
99.4%
efficiency
Watch

Why PulmoSense.

Interactive simulation

Watch the difference in real time.

Switch patient profiles, adjust breathing parameters, and watch PulmoSense outperform a conventional nebulizer live.

The problem

Conventional nebulizers waste most of their drug.

A standard mesh nebulizer runs continuously throughout the breath cycle. During exhalation, aerosol goes into the air instead of the airway. With a typical 1:2 I:E ratio, only one third of the session is useful.

Conventional (1:2 I:E)~67% wasted
Conventional (COPD 1:3 I:E)~75% wasted
PulmoSense (any profile)1–2% wasted

Conventional waste is derived from the inhale fraction of the breath cycle (Ti/T). PulmoSense waste reflects the physical 30 ms piezo mesh decay tail at each inhale-to-exhale transition, validated in simulation.

~67%
of aerosol from a conventional nebulizer is exhaled into the room in a standard adult breathing pattern. For COPD patients with longer exhale ratios, this rises to 75%.
3×
more drug is consumed in a conventional session to deliver the same dose to the lungs , meaningful for expensive biologics and high-frequency treatments.
98–99%
inhale-phase delivery efficiency in PulmoSense in-silico validation across all four patient profiles, using validated per-profile PID gains and a Simulink closed-loop model.
How it works

Smarter delivery. Less waste.

PulmoSense knows when you are breathing in. It delivers medication only during that window , and stops the moment you exhale. That's it.

Step 1
Detect the breath
The device continuously monitors your breathing pattern and detects the precise moment inhalation begins.
Step 2
Deliver during inhale
Aerosol is released only during the inhalation phase , the only window where medication can actually reach the lungs.
Step 3
Stop on exhale
The moment exhalation starts, delivery stops. No drug lost to the air. No wasted dose. Every milligram goes where it's meant to go.
Validated results

In-silico performance across all four patient profiles.

Phase 1 in-silico validation report (v2.3). Per-profile PID gains tuned in simulation and validated in the Simulink closed-loop model.

Normal Adult
99.4%
Inhale-phase delivery
Kp 2.000
Ki 1.000
Kd 0.033
Pediatric
98.8%
Inhale-phase delivery
Kp 0.109
Ki 1.000
Kd 0.083
COPD
98.0%
Inhale-phase delivery
Kp 0.100
Ki 1.000
Kd 0.026
Asthma
98.0%
Inhale-phase delivery
Kp 0.100
Ki 1.000
Kd 0.016
Phase 1 in-silico pre-validation only. Per FDA Modernization Act 2.0 (2022) and ANVISA RDC 751/2022, computational simulation is accepted as pre-clinical validation evidence. Bench testing on physical hardware is required before any clinical or regulatory submission.
Team

Built at the intersection of engineering and clinical need.

Founder & Engineer
Fahad Alhuthaifi
PulmoSense LLC
M.Eng. Biomedical Engineering, Cornell University (2025). Background in clinical and process engineering. Founded PulmoSense to solve the drug waste problem in nebulizer therapy through smart breath-synchronized delivery.
Main Advisor & Academic Partner
Prof. Suélia S. R. Fleury Rosa
University of Brasília · Cornell University
Associate Professor of Biomedical Engineering at UnB with a postdoctorate from MIT Media Lab. Expert in physiological systems modeling, in-silico simulation of biological systems, and medical device development through Phase I–IV clinical trials. Main academic advisor on PulmoSense, providing expertise in translational health research and regulatory pathway to ANVISA and CONEP.
Clinical & Brazil Partner
BioEny
Brazil · Ana Karoline, Director of Tissue Engineering
Clinical development and Brazil market partner. Collaborating on manuscript, patient data, and pathway to first-in-human validation in the Brazilian regulatory framework.
Contact

Interested in partnering or investing?

PulmoSense is at the in-silico pre-validation stage. Seeking partners for PCB design and fabrication and conversations with strategic investors in respiratory drug delivery.

Get in touch Explore the simulation